ATE164311T1 - Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten - Google Patents

Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten

Info

Publication number
ATE164311T1
ATE164311T1 AT94916352T AT94916352T ATE164311T1 AT E164311 T1 ATE164311 T1 AT E164311T1 AT 94916352 T AT94916352 T AT 94916352T AT 94916352 T AT94916352 T AT 94916352T AT E164311 T1 ATE164311 T1 AT E164311T1
Authority
AT
Austria
Prior art keywords
protein
peptides
pharmaceutical compositions
antibodies
compositions containing
Prior art date
Application number
AT94916352T
Other languages
English (en)
Inventor
Michael Waddington Smith
Original Assignee
Babraham Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Inst filed Critical Babraham Inst
Application granted granted Critical
Publication of ATE164311T1 publication Critical patent/ATE164311T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6943—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a pill, a tablet, a lozenge or a capsule

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94916352T 1993-06-03 1994-06-02 Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten ATE164311T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939311454A GB9311454D0 (en) 1993-06-03 1993-06-03 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE164311T1 true ATE164311T1 (de) 1998-04-15

Family

ID=10736565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916352T ATE164311T1 (de) 1993-06-03 1994-06-02 Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten

Country Status (9)

Country Link
EP (1) EP0707473B1 (de)
AT (1) ATE164311T1 (de)
AU (1) AU6804394A (de)
DE (1) DE69409237T2 (de)
DK (1) DK0707473T3 (de)
ES (1) ES2117272T3 (de)
GB (1) GB9311454D0 (de)
WO (1) WO1994028879A1 (de)
ZA (1) ZA943920B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1275380A1 (de) * 1997-01-30 2003-01-15 Chiron Corporation Verwendung von Mikropartikeln mit adsorbiertem Antigen zur Stimulierung der Immunabwehr
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ES2195317T3 (es) 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
IT1291559B1 (it) * 1997-04-14 1999-01-11 Univ Degli Studi Milano Uso di microparticelle su cui sono stati adsorbiti una proteina ed un anticorpo per preparare una composizione farmaceutica somministrabile
WO2002026212A2 (en) 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
EP1558645B1 (de) 2002-11-08 2011-07-27 Ablynx N.V. Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595826B1 (fr) * 1986-03-13 1990-09-07 Lurhuma Zirimwabagabo Produit d'immuno-essai, son procede de preparation, son utilisation, complexe immunogene le comportant et utilisation de ce complexe
DK0531497T3 (da) * 1991-04-02 1998-03-23 Biotech Australia Pty Ltd Orale indgivelsessystemer til mikropartikler

Also Published As

Publication number Publication date
GB9311454D0 (en) 1993-07-21
DE69409237D1 (de) 1998-04-30
DE69409237T2 (de) 1998-10-29
ZA943920B (en) 1995-12-04
WO1994028879A1 (en) 1994-12-22
EP0707473A1 (de) 1996-04-24
EP0707473B1 (de) 1998-03-25
ES2117272T3 (es) 1998-08-01
DK0707473T3 (da) 1999-01-04
AU6804394A (en) 1995-01-03

Similar Documents

Publication Publication Date Title
NO962346L (no) Humaniserte antistoffer og anvendelser derav
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
ATE189611T1 (de) Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten
BR8906988A (pt) Tetrapiptidio,peptidio,composicao farmaceutica,processo para uso de peptidio e reagente para diagnostico
DK184890D0 (da) Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme
DK614987A (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
DE68925226D1 (de) Monoklonale Antikörper
IL96907A0 (en) Proteins produced by human lymphocytes,a dna sequence coding for said proteins and their pharmaceutical and biological application
DK110183D0 (da) Carboxyalkyldipeptider, fremgangsmade til deres fremstilling samt farmaceutiske praeparater indeholdende disse
NL194828B (nl) Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten.
KR900013979A (ko) 사람 유두종비루스형 16의 e7 단백질상의 면역원성 영역
DK235687D0 (da) Tilberedninger til syntese af prostaglandiner og hydroxyfedtsyrer i biologiske systemer og anvendelse deraf
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
DE69409237D1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
ES2118939T3 (es) Peptido para el diagnostico e inmunizacion contra la infeccion con t.cruzi.
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
ATE48142T1 (de) Blutprotein, verfahren zu seiner herstellung, antikoerper gegen dieses protein und dieses protein oder diese antikoerper enthaltende pharmazeutische zubereitungen.
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
ATE67210T1 (de) Androstane-17-beta-carbonsaeureester, verfahren zu deren herstellung und pharmazeutische praeparate die diese enthalten.
AR004377A1 (es) UNA PROTEINA BIOLOGICAMENTE ACTIVA INHIBIDORA DE KAPA B (NF k B), UNA SECUENCIA DE ACIDO NUCLEICO, UN VECTOR DE EXPRESION, UN ANTICUERPO CONTRADICHA PROTEINA, UN PROCESO PARA SU PREPARACION, UNA COMPOSICION FARMACEUTICA Y EL USO DE DICHA PROTEINA PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS.
FI904087A7 (fi) Monoklonaalisia vasta-aineita aktivoituja ras-proteiineja vastaan, joi lla on aminohappomutaatioita proteiinin kohdassa 13
KR900701300A (ko) 생물학적 활성 펩티드 및 특정음이온을 갖는 조성물 및 이것을 사용하는 방법
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee